UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

There have been great advances in the field of generalised myasthenia gravis (gMG) in recent years ... and John Vissing, Copenhagen Neuromuscular Centre, Rigshospitalet, Denmark, share their expert ...

Large-scale studies are needed to confirm these findings. Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction; it is primarily caused by the production of ...

Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction that causes fatigable neuromuscular weakness. 85% of patients have antibodies against the acetylcholine receptor (AChR) ...

Medications for myasthenia gravis (MG ... Eculizumab helps prevent neuromuscular junction damage. You’ll receive it weekly for 4 weeks, followed by every 2 weeks, and is approved for people ...

Myasthenia gravis (MG) is an autoimmune disorder involving ... Since DJ-1 also plays a key role in neuromuscular junction protection, it is speculated that its abnormalities may mediate the ...

Among the Medicare Fee-For-Service-covered elderly US population, myasthenia gravis prevalence and incidence rates have consistently increased between 2006 and 2019. Between 2006 and 2019 ...

Congenital myasthenic syndromes (CMSs) are a heterogeneous group of disorders that affect the safety margin of neuromuscular transmission — the depolarization that is required for propagation of ...

Test Your Knowledge About the Surgical Management of Myasthenia Gravis Test Your Knowledge About the Histology of Myasthenia Gravis Test Your Knowledge About the Clinical Features of Myasthenia Gravis ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.